• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Haemonetics Corporation

    6/2/25 1:16:13 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care
    Get the next $HAE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001420910
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    HAEMONETICS CORP
    SEC File Number
    001-14041
    Address of Issuer
    125 SUMMER STREET
    BOSTON
    MASSACHUSETTS
    02110
    Phone
    7818487100
    Name of Person for Whose Account the Securities are To Be Sold
    Strong Stewart W
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    2835191277.454803699606/02/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/15/2025Restricted Stock VestingIssuerCheckbox not checked70605/15/2025Compensation
    Common05/16/2025Restricted Stock VestingIssuerCheckbox not checked77905/16/2025Compensation
    Common05/17/2025Restricted Stock VestingIssuerCheckbox not checked72305/17/2025Compensation
    Common05/18/2025Restricted Stock VestingIssuerCheckbox not checked62705/18/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/02/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    02/13/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Stewart Strong

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $HAE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HAE

    DatePrice TargetRatingAnalyst
    7/9/2025$90.00Neutral → Buy
    Citigroup
    6/26/2025$87.00Outperform
    Robert W. Baird
    2/7/2025$95.00 → $68.00Neutral → Underperform
    BofA Securities
    12/6/2024$116.00Overweight
    Analyst
    11/8/2024$120.00Outperform → Strong Buy
    Raymond James
    9/13/2024$116.00Buy
    CL King
    9/11/2024$85.00Neutral
    BofA Securities
    9/10/2024$112.00Buy
    BTIG Research
    More analyst ratings

    $HAE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: EVP and General Counsel Basil Michelle L was granted 6,755 shares, increasing direct ownership by 24% to 35,233 units (SEC Form 4)

      4/A - HAEMONETICS CORP (0000313143) (Issuer)

      6/13/25 4:26:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Amendment: EVP, Chief Commercial Officer Galvin Roy was granted 5,689 shares, increasing direct ownership by 79% to 12,932 units (SEC Form 4)

      4/A - HAEMONETICS CORP (0000313143) (Issuer)

      6/13/25 4:21:06 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SVP, Human Resources Miller Laurie A. was granted 3,195 shares, increasing direct ownership by 12% to 29,163 units (SEC Form 4)

      4 - HAEMONETICS CORP (0000313143) (Issuer)

      6/9/25 4:54:35 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

      BOSTON, July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025. The call can be accessed via teleconference at: Q1 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W

      7/9/25 4:05:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe

      Regulatory progress underscores global momentum for PerQseal Elite in transforming large-bore vascular closure Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PerQseal® Elite vascular closure system for arterial procedures. The submission builds upon the successful results of the PATCH study as well as positive clinical use in Europe, reinforcing the system's potential safety and performance profile. In addition, the company received European CE mark approval for an expanded indication for PerQseal Elite

      6/24/25 8:00:00 AM ET
      $HAE
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products
    • Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      BOSTON, May 30, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:40 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1721260&tp_key=3096fdc651&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be availab

      5/30/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    SEC Filings

    See more
    • SEC Form 144 filed by Haemonetics Corporation

      144 - HAEMONETICS CORP (0000313143) (Subject)

      6/12/25 4:51:50 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Haemonetics Corporation

      DEFA14A - HAEMONETICS CORP (0000313143) (Filer)

      6/6/25 4:18:27 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Haemonetics Corporation

      DEF 14A - HAEMONETICS CORP (0000313143) (Filer)

      6/6/25 4:17:37 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Haemonetics upgraded by Citigroup with a new price target

      Citigroup upgraded Haemonetics from Neutral to Buy and set a new price target of $90.00

      7/9/25 8:09:33 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Haemonetics with a new price target

      Robert W. Baird initiated coverage of Haemonetics with a rating of Outperform and set a new price target of $87.00

      6/26/25 8:10:13 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Haemonetics from Neutral to Underperform and set a new price target of $68.00 from $95.00 previously

      2/7/25 8:24:25 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Sotera Health Appoints Christopher Simon to the Board of Directors

      CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

      8/1/24 7:00:02 AM ET
      $HAE
      $SHC
      Medical/Dental Instruments
      Health Care
      Misc Health and Biotechnology Services
    • Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

      BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the

      10/4/22 6:51:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Financials

    Live finance-specific insights

    See more
    • Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

      BOSTON, July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025. The call can be accessed via teleconference at: Q1 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W

      7/9/25 4:05:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

      5/8/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

      BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

      3/31/25 4:00:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Haemonetics Corporation

      SC 13G - HAEMONETICS CORP (0000313143) (Subject)

      11/14/24 1:28:29 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

      SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

      11/12/24 12:54:20 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

      SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

      11/8/24 10:41:07 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care